NAD Supplementation in Parkinson's Disease
NCT07703137
Basal Ganglia Diseases, Brain Diseases
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT Number: NCT07622303
This study aims to assess the prevalence and severity of depression, anxiety, and sleep disorders among patients with idiopathic Parkinson's disease. The study will evaluate the relationship between neuropsychiatric symptoms and disease characteristics in order to improve early recognition and patient quality of life.
Trial opening soon.
Get Notified50 year and older
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
A-Inclusion Criteria:
B-Exclusion Criteria:
6-Patients with unstable medical conditions. 7-Patients unable or unwilling to provide informed consent.
Time frame: Baseline assessment during study enrollment.
Depression severity measured using the Hamilton Depression Rating Scale (HAM-D). Scores range from 0 to 52, with higher scores indicating more severe depression.
Time frame: Baseline
Anxiety severity measured using the Hamilton Anxiety Rating Scale (HAM-A). Scores range from 0 to 56, with higher scores indicating more severe anxiety.
Time frame: Baseline
Sleep disturbance measured using the Parkinson's Disease Sleep Scale (PDSS). Higher scores indicate better sleep quality and fewer sleep-related symptoms.
Sohag University
Other
Assessment of Depression , Anxiety and Sleep Disorders in Patients With Idiopathic Parkinson's Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07703137
Basal Ganglia Diseases, Brain Diseases
Oklahoma City, Oklahoma, United States
View Trial DetailsNCT07653256
Balance Control, Basal Ganglia Diseases
View Trial DetailsNCT07384429
Basal Ganglia Diseases, Brain Diseases
Wuhan, Hubei, China
View Trial DetailsNCT07384442
Basal Ganglia Diseases, Brain Diseases
Wuhan, Hubei, China
View Trial Details